Pharmacogenomics for Adverse Drug Reactions

Pharmacogenomics have long held the promise of using personalized information for drug selection to maximize efficacy and minimize adverse reactions. A new study evaluates the routine use of pharmacogenomic testing to improve safety in a wide range of medications. Join host, Geoff Wall, as he evaluates personalized medicine.

The GameChanger
Most studies using routine pharmacogenomic testing in clinical practice have not been significant. However, a new study found a 12 panel pharmacogenomic test did decrease the incidence of patient reported adverse effects compared to usual care. Several limitations still exist preventing widespread implementation.

Show Segments
00:00 - Introductions
01:38 - Genomic Guided Therapy to Date
05:05 - Importance of Genomic Variations
08:37 - Looking at the Study
21:20 - The GameChanger: Swen et al Results
27:50 - Connecting to Practice: Current Barriers to Pharmacogenomic Testing
30:38- Closing Remarks

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.

Clinical Pharmacogenomics Implementation Consortium.

Redeem your CPE here
CPE (Pharmacist)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Pharmacists: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe current barriers to routine use of pharmacogenomic testing
2. Discuss issues and results of the Swen et al study on pharmacogenomics

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-118-H01-P
Initial release date: 03/20/2023
Expiration date: 03/20/2024
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram